Avacta Group (LON:AVCT) Stock Passes Above 50 Day Moving Average - Here's Why

Key Points

• Avacta Group stock crossed above its 50-day moving average (50-day MA GBX 64.94) during Wednesday trading, traded as high as GBX 78 and last traded at GBX 74 on a volume of 3,348,313 shares.
• Key financials: market capitalization £335.59 million, a negative P/E of -4.22, current ratio 0.79, quick ratio 4.96, and a very high reported debt-to-equity ratio of 14,168.75.
• Business profile: Avacta is a clinical-stage biopharmaceutical developing the pre|CISION® platform to deliver potent cancer therapeutics activated by the tumor-specific protease FAP.

Avacta Group Plc (LON:AVCT - ) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of GBX 64.94 and traded as high as GBX 78. Avacta Group shares last traded at GBX 74, with a volume of 3,348,313 shares trading hands.

Avacta Group Stock Performance

The business's 50-day moving average is GBX 64.94 and its two-hundred day moving average is GBX 66.01. The company has a current ratio of 0.79, a quick ratio of 4.96 and a debt-to-equity ratio of 14,168.75. The stock has a market capitalization of £335.59 million, a PE ratio of -4.22 and a beta of 1.12.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.